Cardinal Health stays a Buy with strong FY2026 results and promising FY2027 earnings growth guidance.

Cardinal Health reported robust fiscal year 2026 results, including 14% revenue growth, a 20% increase in gross margin, and doubled free cash flow. Despite challenges like thin margins and higher current liabilities, the company remains strong with FY2027 guidance targeting 13-15% non-GAAP EPS growth. Profit improvements are expected from both its Pharmaceutical and Specialty Solutions segments and higher-margin 'Other' segments. The stock valuation is reasonable compared to peers, though risks from macroeconomic factors, reimbursement changes, and margin pressures remain.

As of Oct 01, 2026 02:11 WIB, Cardinal Health (CAH) trades at USD 223.70 on Pluang, close to its 52-week high of USD 248.61 but well above its 52-week low of USD 153.27. The stock shows a slight 1-day decline of 0.09%, with a market cap of $51.85 billion and a dividend yield of 0.92%. Pluang investors currently show full buying interest with 100% buy orders, reflecting confidence despite the small daily dip.